| |
1. Derivation of small-ligand libraries with ligands design to bind to the Thymidylate synthase monomer /monomer interface affecting dimer formation and TS- TSmRNA interactions.
2. Validation of the integrated, multidisciplinary drug design strategy necessary to achieve objective 1, which poses a highly challenging design problem. The strategy including systems pathway studies, protein residue SH and X -labelling to identify low-affinity ligands, peptide mimetic design, and filtering for ADME properties.
3. Identification of small-ligands identified in a chemical-biology approach as effective perturbing agents to investigate the mechanism of resistance against a panel of cis-platinum resistant ovarian carcinoma cell lines.
4. Provide potential drug candidate(s) with new mechanism of action for further development as safer therapeutic agent(s) for the treatment of ovarian carcinoma.
|